Market Overview

From Earlier, Compassionate Use of Pluristem's PLX Cells Saves the Life of a Child After Bone Marrow Transplantation Failure

Pluristem Therapeutics, Inc. (Nasdaq: PSTI) today announced that a seven year-old girl suffering from an aplastic bone marrow whose condition was rapidly deteriorating is now experiencing a reversal of her condition with a significant increase in her red cells, white cells and platelets following the intramuscular injection of the company's PLacental eXpanded (PLX) cells. Aplastic bone marrow is a disease where the patient has no blood-forming hematopoietic stem cells in the bone marrow.

"With her body rejecting all possible treatment – and with no other options – we finally turned to Pluristem's PLX cells, which literally saved her life," said Professor Reuven Or, Director of Bone Marrow Transplantation, Cell Therapy and Transplantation Research Center at Hadassah Medical Center and the child's physician. "The results of this unique case indicate that PLX cells may be effective in treating other diseases that affect the bone marrow."

Posted-In: News FDA

 

Related Articles (PSTI)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters